{"id":"W4385230266","doi":"10.1093/bjd/ljad252","title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Dermatrials Research; Probity Medical Research; University of British Columbia","funders":"National Institutes of Health; AbbVie; Boehringer Ingelheim","keywords":"Apremilast; Medicine; Psoriasis Area and Severity Index; Psoriasis; Randomized controlled trial; Internal medicine; Secukinumab; Clinical endpoint; Dermatology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005673844,0.0002872387,0.002304911,0.0001855374,0.0002824727,0.00005284523,0.000390474,0.000241579,0.000007308186],"category_scores_gemma":[0.0001414226,0.0001953368,0.000207684,0.0001888342,0.0002315099,0.0001328145,0.00003844513,0.000124044,0.000001679318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003586645,"about_ca_system_score_gemma":0.0001886742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004941481,"about_ca_topic_score_gemma":0.0003128578,"domain_scores_codex":[0.996865,0.0007885367,0.00158205,0.0003414285,0.00008523093,0.0003377014],"domain_scores_gemma":[0.9937319,0.003984245,0.001561989,0.00026269,0.0004194627,0.0000397396],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.870071,0.00830485,0.001868859,0.00008547754,0.01094632,0.0002176508,0.009775544,0.0001079171,0.005703421,0.0000325407,0.002604377,0.09028208],"study_design_scores_gemma":[0.9216843,0.007467228,0.0004825285,0.0004763556,0.002060876,0.003945193,0.007111386,0.0007791712,0.05508719,0.0001274576,0.0005328266,0.0002455188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692798,0.02426737,0.001003466,0.0003107736,0.0004068213,0.003762066,0.0009410087,0.00001767286,0.00001105946],"genre_scores_gemma":[0.9906856,0.00802209,0.000448212,0.00001484997,0.00004546489,0.0004938446,0.0002112511,0.00003204167,0.00004660299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09003656,"threshold_uncertainty_score":0.7965603,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06904877460295726,"score_gpt":0.3528525986404932,"score_spread":0.283803824037536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}